Trial · NCT03104400
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Placebo | 36.2 | 95% Confidence Interval 31.6 to 40.7 | percentage of participants | |
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Adalimumab 40 mg | 65.0 | 95% Confidence Interval 60.5 to 69.5 | percentage of participants | |
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Upadacitinib 15 mg | 70.6 | 95% Confidence Interval 66.3 to 74.9 | percentage of participants | |
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Upadacitinib 30 mg | 78.5 | 95% Confidence Interval 74.6 to 82.4 | percentage of participants | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Placebo | -0.14 | 95% Confidence Interval -0.18 to -0.09 | units on a scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Adalimumab 40 mg | -0.34 | 95% Confidence Interval -0.38 to -0.29 | units on a scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Upadacitinib 15 mg | -0.42 | 95% Confidence Interval -0.47 to -0.37 | units on a scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | Upadacitinib 30 mg | -0.47 | 95% Confidence Interval -0.52 to -0.42 | units on a scale | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Placebo | 10.9 | 95% Confidence Interval 7.4 to 14.3 | percentage of participants | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Adalimumab 40 mg | 38.5 | 95% Confidence Interval 33.2 to 43.7 | percentage of participants | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Upadacitinib 15 mg | 41.9 | 95% Confidence Interval 36.5 to 47.3 | percentage of participants | |
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | Upadacitinib 30 mg | 54.0 | 95% Confidence Interval 48.6 to 59.4 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Placebo | 21.3 | 95% Confidence Interval 15.8 to 26.9 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Adalimumab 40 mg | 53.1 | 95% Confidence Interval 46.3 to 59.8 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Upadacitinib 15 mg | 62.6 | 95% Confidence Interval 56.1 to 69.1 | percentage of participants | |
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | Upadacitinib 30 mg | 62.4 | 95% Confidence Interval 55.8 to 68.9 | percentage of participants | |
| Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24 | Placebo | 0.25 | 95% Confidence Interval 0.13 to 0.36 | score on a scale | |
| Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24 | Adalimumab 40 mg | 0.01 | 95% Confidence Interval -0.11 to 0.13 | score on a scale | |
| Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24 | Upadacitinib 15 mg | -0.04 | 95% Confidence Interval -0.16 to 0.07 | score on a scale | |
| Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24 | Upadacitinib 30 mg | 0.03 | 95% Confidence Interval -0.08 to 0.15 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03104400/results